La Jolla California UNITED STATES
Mark Wilson is CEO of MatriSys Bioscience, Inc. Mr. Wilson, who holds a MBA from UCLS, has been in biopharmaceutical development for nearly 30 years in San Diego, having started at the first antibody company in the world, Hybritech. Mr. Wilson then joined Halozyme Therapeutics and brought in a $612 million, 13-product deal with Hoffmann-La Roche. Halozyme is now a more than $2.8 billion company in San Diego. Mr. Wilson cofounded MatriSys Bioscience with Dr. Lou Bookbinder, Dr. Gilbert Keller, and Prof. R. Gallo who is Chair of the Department of Dermatology at UCSD and a world leader in the Bioscience focuses on the $142 Billion worldwide dermatology and skin care market by developing microbiome derived therapies for the top dermatology and skin care conditions – Acne, Atopic Dermatitis, Rosacea, Psoriasis, and Skin Infections which have a huge impact on 230 million patients’ quality of life, which represent a $13 Billion Rx market and a $120 Billion skin care market.